- Home
- ALLY vs QGEN Comparison
ALLY vs QGEN Comparison
Compare ALLY & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLY
- QGEN
- Stock Information
- Founded
- ALLY 1919
- QGEN 1986
- Country
- ALLY United States
- QGEN Netherlands
- Employees
- ALLY N/A
- QGEN N/A
- Industry
- ALLY Major Banks
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLY Finance
- QGEN Health Care
- Exchange
- ALLY Nasdaq
- QGEN Nasdaq
- Market Cap
- ALLY 11.3B
- QGEN 9.1B
- IPO Year
- ALLY 2014
- QGEN 1996
- Fundamental
- Price
- ALLY $36.95
- QGEN $46.76
- Analyst Decision
- ALLY Buy
- QGEN Buy
- Analyst Count
- ALLY 19
- QGEN 7
- Target Price
- ALLY $43.19
- QGEN $49.51
- AVG Volume (30 Days)
- ALLY 4.6M
- QGEN 1.4M
- Earning Date
- ALLY 07-18-2025
- QGEN 07-30-2025
- Dividend Yield
- ALLY 3.24%
- QGEN 2.83%
- EPS Growth
- ALLY N/A
- QGEN N/A
- EPS
- ALLY 0.61
- QGEN 0.42
- Revenue
- ALLY $6,658,000,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- ALLY $20.15
- QGEN $6.36
- Revenue Next Year
- ALLY $14.71
- QGEN $6.18
- P/E Ratio
- ALLY $60.50
- QGEN $110.70
- Revenue Growth
- ALLY N/A
- QGEN 3.31
- 52 Week Low
- ALLY $29.52
- QGEN $37.63
- 52 Week High
- ALLY $45.46
- QGEN $47.93
- Technical
- Relative Strength Index (RSI)
- ALLY 59.20
- QGEN 64.44
- Support Level
- ALLY $35.94
- QGEN $46.25
- Resistance Level
- ALLY $38.05
- QGEN $47.70
- Average True Range (ATR)
- ALLY 0.76
- QGEN 0.62
- MACD
- ALLY 0.03
- QGEN -0.00
- Stochastic Oscillator
- ALLY 70.53
- QGEN 68.56
About ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).